Already positive, the research from JP Morgan and its analyst Richard Vosser still consider the stock as a Buy opportunity. The target price continues to be set at EUR 105. | April 17, 2023
Sanofi SA and AstraZeneca PLC said Tuesday that Sanofi would retain full commercial control on an antibody treatment for respiratory syncytial virus in the U.S. Sanofi Gets Full Commercial Control. | April 11, 2023
Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements Modification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and. | April 11, 2023
AstraZeneca PLC on Tuesday said it has simplified its contract with Sanofi SA and Swedish Orphan Biovitrum, or Sobi, relating to the development and commercialisation of nirsevimab in the US, while. | April 11, 2023
By Cecilia Butini Sanofi SA and AstraZeneca PLC said Monday that Sanofi would retain full commercial control on an antibody treatment for respiratory syncytial virus in the U.S. as part of a. | April 11, 2023